As a leader in tumor metabolism and fibrosis, ImmunoMet Therapeutics is developing novel chemical entities modulating critical metabolic functions in tumor, fibrotic, and other OxPhos-sensitive cells.  Our lead clinical compound, lixumistat (IM156), is intended to eliminate tumors by preferentially targeting resistant subpopulations of cells, primarily in combination with current standard of care therapies.  In fibrosis, lixumistat (IM156) mitigates the formation of myofibroblasts, thereby potentially preventing both the initiation of and advancement of fibrosis.